Tagrisso approved in the EU for the adjuvant treatment of patients with early-stage EGFR-mutated…
AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor…
Read More...
Read More...
